Jacob S. Ballon, MD, MPH, is affiliated with the Department of Psychiatry at Stanford University. His publications span from 2002 to 2024 and focus on clinical topics including bipolar disorder, major depressive disorder, neurology, and schizophrenia/schizoaffective disorders. His work includes studies on the long-term safety and tolerability of antipsychotic treatments, systematic reviews of pharmacologic agents such as modafinil, and the metabolic effects of novel antipsychotics. He has frequently collaborated with Christina Arevalo, Christoph U. Correll, David Feifel, David McDonnell, and Donna A. Wirshing.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
